(NASDAQ: BEAM) Beam Therapeutics's forecast annual revenue growth rate of -44.84% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.42%.
Beam Therapeutics's revenue in 2024 is $352,567,000.On average, 7 Wall Street analysts forecast BEAM's revenue for 2024 to be $4,221,163,174, with the lowest BEAM revenue forecast at $2,406,536,075, and the highest BEAM revenue forecast at $6,181,171,425. On average, 6 Wall Street analysts forecast BEAM's revenue for 2025 to be $5,425,667,446, with the lowest BEAM revenue forecast at $1,648,312,380, and the highest BEAM revenue forecast at $8,241,561,900.
In 2026, BEAM is forecast to generate $4,334,402,234 in revenue, with the lowest revenue forecast at $30,493,779 and the highest revenue forecast at $9,065,718,090.